9 Jun,2021 | Industry Leaders Magazine, Leadership
The Food and Drug Administration of the US approved on Monday Biogen Inc’s Aducanumab to treat Alzheimer’s disease amidst the controversy of its efficacy. Biogen has priced the drug at $56,000 per year, which has led to questions over the high cost of...
